Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review

Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. How...

Full description

Bibliographic Details
Main Authors:	Caitlin Lazurko, Revital Linder, Kate Pulman, Genevieve Lennox, Tomer Feigenberg, Rouhi Fazelzad, Taymaa May, Tiffany Zigras
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Current Oncology
Subjects:	low-grade serous ovarian cancer bevacizumab overall response rate
Online Access:	https://www.mdpi.com/1718-7729/30/9/592

Similar Items

Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy
by: Yoo-Ri Chung, et al.
Published: (2022-06-01)

Identifying Borderline Ovarian Tumor Recurrence Using Routine Ultrasound Follow-Up
by: Caitlin Lazurko, et al.
Published: (2022-12-01)

Intravitreal Bevacizumab for Photodynamic Therapy-Induced Massive Macular Detachment in Acute Central Serous Chorioretinopathy
by: Maria G. Kotoula, et al.
Published: (2012-06-01)

Intravitreal bevacizumab for treatment of central serous chorioretinopathy
by: Cihan Ünlü, et al.
Published: (2016-01-01)

Effect of Intravitreal Injection of Bevacizumab on Acute Central Serous Chorioretinopathy Patients who Visited Feiz Hospital during 2014–2015 Period
by: Mohamad Reza Akhlaghi, et al.
Published: (2017-01-01)

Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
by: Aditya Kelkar, et al.
Published: (2014-07-01)

The Effect of Metabolic Diseases on the Outcome of Bevacizumab Injection for Central Serous Retinopathy
by: M Babaei, et al.
Published: (2022-03-01)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
by: Renan Ribeiro e Ribeiro, et al.
Published: (2021-05-01)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
by: Martin Svoboda, et al.
Published: (2018-08-01)

Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer
by: Jung Mi Byun, et al.
Published: (2023-01-01)

Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization
by: Farhad Fazel Najafabadi, et al.
Published: (2015-01-01)

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
by: Zhongshao Chen, et al.
Published: (2022-09-01)

Immunoexpression of p53 and p16 in Low and High-grade Serous Ovarian Cancer: A Cross-sectional Study
by: Ranajit Mandal, et al.
Published: (2023-11-01)

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
by: Zibi Marchocki, et al.
Published: (2022-05-01)

Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database
by: Xiaoduo Li, et al.
Published: (2021-02-01)

Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
by: Elena Mairinger, et al.
Published: (2023-11-01)

Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer
by: Jun Jiang, et al.
Published: (2021-01-01)

Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high‐grade serous ovarian cancer
by: Guodong Zhang, et al.
Published: (2021-06-01)

High-grade versus low-grade serous carcinoma of the ovary – current differential diagnosis and perspectives
by: Manuela POPA, et al.
Published: (2018-12-01)

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
by: Kristýna Němejcová, et al.
Published: (2023-02-01)

Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019-07-01)

Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
by: Shuqing Li, et al.
Published: (2020-08-01)

Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy
by: Srikant Padhy, et al.
Published: (2018-01-01)

Bilateral low grade serous adenocarcinoma of the ovaries in a badger (Meles meles L.) and its association with a borderline serous ovarian tumour: a case report
by: K. Kutlvasr, et al.
Published: (2014-01-01)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
by: Michalis Liontos, et al.
Published: (2021-03-01)

Comparison between the functional and anatomical outcomes of full-dose, half-dose photodynamic therapy and intravitreal bevacizumab in chronic central serous chorioretinopathy
by: Abdelrahman G Salman
Published: (2015-01-01)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
by: Irena Conic, et al.
Published: (2022-04-01)

Bilateral multiple serous retinal detachments following bone marrow transplantation
by: Pejvak Azadi, et al.
Published: (2019-01-01)

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis
by: Christoph Wohlmuth, et al.
Published: (2022-04-01)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
by: Maria Vias, et al.
Published: (2023-05-01)

The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature
by: Paulina Haight, et al.
Published: (2021-05-01)

Analysis on Bevacizumab with PDT for CSC
by: Min Yang, et al.
Published: (2018-05-01)

CT features of low grade serous carcinoma of the ovary
by: Harpreet K. Pannu
Published: (2015-01-01)

Ovarian high-grade serous carcinoma with estrogenic manifestations in a postmenopausal woman: A case report
by: Akihiro Takeda, et al.
Published: (2023-03-01)

FREQUENCY OF NAPSIN A POSITIVITY IN OVARIAN CLEAR CELL CARCINOMA AND SEROUS CARCINOMA
by: Zara Saeed, et al.
Published: (2018-08-01)

Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database
by: Pei Luo, et al.
Published: (2019-12-01)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
by: Puja Dey, et al.
Published: (2022-03-01)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
by: Chunlong Huang, et al.
Published: (2021-01-01)

Cell Origins of High-Grade Serous Ovarian Cancer
by: Jaeyeon Kim, et al.
Published: (2018-11-01)